1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Sleep Disorders - Pipeline Review, H2 2013

Sleep Disorders - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 60 pages

Sleep Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Sleep Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sleep Disorders. Sleep Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sleep Disorders.
- A review of the Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sleep Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sleep Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sleep Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Sleep Disorders - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sleep Disorders Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Sleep Disorders 8
Sleep Disorders Therapeutics under Development by Companies 10
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Sleep Disorders Therapeutics - Products under Development by Companies 15
Companies Involved in Sleep Disorders Therapeutics Development 16
Athersys, Inc. 16
Ono Pharmaceutical Co., Ltd. 17
Teva Pharmaceutical Industries Limited 18
NovaDel Pharma, Inc. 19
Neurim Pharmaceuticals (1991) Ltd. 20
CoLucid Pharmaceuticals, Inc. 21
Ferrer Internacional S.A. 22
Sleep Disorders - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Histamine H3 Receptor Antagonists - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Neu-P11 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
zolpidem tartrate - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
CR-5542 Series - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
melatonin - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
COL-204 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
ABT-652 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
SKL-N05 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Conjugated Stigmine Program - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Casein Kinase 1 Delta Project - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Drug Targeting GABA Alpha 4 Delta Receptor - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Compound-16 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
sodium oxybate IR - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
ONO-4127 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
sodium oxybate MR - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Sleep Disorders Therapeutics - Drug Profile Updates 46
Sleep Disorders Therapeutics - Discontinued Products 49
Sleep Disorders Therapeutics - Dormant Products 50
Sleep Disorders - Product Development Milestones 51
Featured News and Press Releases 51
Aug 10, 2012: Mylan Launches Generic Provigil Tablets 51
Jul 23, 2012: Mitsubishi Tanabe Pharma Announces Launch Of Tranquilizer Depas Tablets 0.25Mg 51
Nov 25, 2011: Alfresa And Mitsubishi Tanabe Pharma Announce Approval Of Additional Indication For Modiodal Tablets 100mg 51
Nov 25, 2011: Alfresa Holdings And Mitsubishi Tanabe Pharma Announce Approval Of Additional Indication For Modiodal Tablets 52
May 20, 2011: VIVUS Announces Multiple Presentations Featuring QNEXA Data To Be Presented At European Congress On Obesity 52
May 06, 2011: Cephalon Reports Positive Phase IV Trial Results With NUVIGIL In Largest Shift Work Disorder Trial 53
Jan 10, 2011: Shire Reports Positive Signal Finding Study Of Investigative Use Of Vyvanse Capsules CII In Excessive Daytime Sleepiness Model 54
Nov 18, 2010: European Medicines Agency Recommends Restricting Use Of Modafinil 55
Jun 09, 2010: Merck Announces Phase IIb Study Results Of Investigational Insomnia Therapy Drug MK-4305 55
Jun 09, 2010: Study Says Somnus's SKP-1041 May Prevent Middle-Of-The-Night Awakening With No Adverse Effects On Next Day Performance 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Tables

Number of Products Under Development for Sleep Disorders, H2 2013 8
Products under Development for Sleep Disorders - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Athersys, Inc., H2 2013 16
Ono Pharmaceutical Co., Ltd., H2 2013 17
Teva Pharmaceutical Industries Limited, H2 2013 18
NovaDel Pharma, Inc., H2 2013 19
Neurim Pharmaceuticals (1991) Ltd., H2 2013 20
CoLucid Pharmaceuticals, Inc., H2 2013 21
Ferrer Internacional S.A., H2 2013 22
Assessment by Monotherapy Products, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 27
Sleep Disorders Therapeutics - Drug Profile Updates 46
Sleep Disorders Therapeutics - Discontinued Products 49
Sleep Disorders Therapeutics - Dormant Products 50

List of Figures

Number of Products under Development for Sleep Disorders, H2 2013 8
Products under Development for Sleep Disorders - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Discovery and Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 23
Assessment by Route of Administration, H2 2013 24
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Molecule Type, H2 2013 26
Assessment by Stage and Molecule Type, H2 2013 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H2 2016

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, ...

Insomnia - Pipeline Review, H2 2016

Insomnia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Insomnia - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Insomnia – Pipeline Review, H2 2016, provides an overview of the Insomnia ...

Insomnia - Pipeline Review, H1 2016

Insomnia - Pipeline Review, H1 2016

  • $ 2000
  • Company report
  • May 2016
  • by Global Markets Direct

Insomnia - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Insomnia - Pipeline Review, H1 2016’, provides an overview of the Insomnia pipeline landscape. The report provides comprehensive ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.